Redcare Pharmacy Faces Mounting Pressure from German Retail Giants

Redcare Pharmacy slashes OTC growth & margin targets amid new competition from dm and Rossmann's online pharmacies, while its prescription drug business remains protected.

The competitive landscape for online pharmacies in Germany is intensifying, with traditional drugstore chains making significant inroads. Redcare Pharmacy, a major player in the sector, is feeling the direct impact, compelling it to revise key financial targets downward. The company's recent strategic adjustments highlight a market in flux.

Revised Targets Signal Challenging Environment

In response to shifting market dynamics, Redcare Pharmacy has substantially moderated its near-term expectations. The company's growth target for over-the-counter (OTC) products has been cut in half, moving from an initial projection of 16% down to a range of 8–10%. Concurrently, the medium-term goal for its EBITDA margin has been lowered from 8% to 5%. This recalibration has coincided with a steep decline in the company's share price, which has lost approximately half its value since the start of the year and currently trades at a multi-year low.

Retail Heavyweights Enter the Fray

The primary source of this pressure stems from the strategic moves of Germany's leading drugstore chains. In December 2025, dm launched its own platform, "dm-med." Its main competitor, Rossmann, is following suit with plans for a dedicated online pharmacy service. This new offering is slated to be accessible directly through Rossmann's existing app, which boasts a user base of around 11 million. Operations will be facilitated through the Netherlands, where a "Rossmann-Apotheke" is already registered in Emmen.

The Prescription Business Remains a Fortress

Amid this competitive onslaught, Redcare's core strength lies in a legally protected segment. German regulations prohibit drugstore chains from selling prescription medications (Rx). Redcare has fortified its position in this arena by securing a CardLink license valid until January 2027 and integrating the national GesundheitsID.

The financial significance of this segment is substantial. In 2025, Redcare generated €503 million in Rx revenue in Germany alone, capturing a 67% market share. Group-wide, prescription revenue surpassed the billion-euro mark for the first time, surging 42.6% to €1.07 billion. For 2026, the company is targeting German Rx revenues exceeding €670 million, a goal driven by the continued rollout of the national e-prescription system.

Leadership in Transition

This period of strategic challenge coincides with a sweeping change in corporate governance. At the Annual General Meeting scheduled for April 15, 2026, a significant board refresh is on the agenda. Anja Hendel, Max Müller, and Peter Schmid von Linstow are set to join the Supervisory Board. Three current members will depart, including two founding shareholders who have served since the company's 2016 IPO.

Furthermore, a new Chief Financial Officer has been designated. Hendrik Krampe, who brings eleven years of experience from Amazon—most recently serving eight years as Finance Director for its European Marketplace business—is poised to take the CFO role.

Market Sentiment and the Upcoming Test

Analyst opinions on Redcare's stock currently show cautious optimism amid the uncertainty. Out of nine market experts covering the company, seven recommend buying the shares, while two advocate holding. The average price target stands at €94.94, though the wide range—from €54 to €150—underscores the significant divergence in views on the company's prospects.

The first concrete test for the new leadership and revised strategy will come with the quarterly results announcement on May 6, 2026. This report will reveal whether the management team can act swiftly enough to support the company's lowered annual targets, which include revenue growth of 13–15% and an adjusted EBITDA margin of at least 2.5%.